EUVIMEDEUVIMED entdecken
Crossref

Nectin‐4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin

Woo Cheal Cho iD, Rayan Saade, Priyadharsini Nagarajan iD, Phyu P Aung iD, Denái R Milton, Mario L Marques-Piubelli iD, Courtney Hudgens, Debora Ledesma, Kelly Nelson, Doina Ivan iD, Miao Zhang, Carlos A Torres-Cabala iD und 6 weitere

Journal of Cutaneous Pathology · 2024

DOI: 10.1111/cup.14579 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cutaneous Pathology, 2024. Verfasst von Woo Cheal Cho und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Adenocarcinoma, Papillary, Antibodies, Monoclonal, Nectins, Neoplasms, Adnexal and Skin Appendage. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Enfortumab vedotin (EV) is an antibody‐drug conjugate directed against Nectin‐4 that is used to treat urothelial carcinoma. Nectin‐4 is inherently expressed in the skin and adnexal structures. Since therapeutic options for cutaneous adnexal carcinomas are limited, we sought to evaluate Nectin‐4 expression in adnexal carcinomas and benign adnexal neoplasms to identify tumors that are potentially targetable with EV.

Methods

Eight sebaceous carcinomas (seven periocular and one lymph node metastasis), eight digital papillary adenocarcinomas, seven squamoid eccrine ductal carcinomas, eight poromas, eight trichilemmomas, and seven sebaceous adenomas were subjected to immunohistochemical staining for anti‐Nectin‐4 antibody. H‐scores for Nectin‐4 expression were calculated.

Results

Benign adnexal neoplasms had a significantly lower mean (±SD) Nectin‐4 H‐score (142.6 ± 39.1) than did the adnexal carcinomas (198 ± 90.8; p = 0.006). Nectin‐4 was expressed in 91% (21/23) of adnexal carcinomas. Sebaceous carcinomas frequently exhibited high expression of Nectin‐4 (88% [7/8]), with a mean (±SD) H‐score (258.1 ± 58.4) significantly higher than those for digital papillary adenocarcinomas (197.5 ± 52.5; p = 0.035) and squamoid eccrine ductal carcinomas (131.4 ± 114.1; p = 0.031). Sebaceous carcinomas also had significantly higher H‐scores than did sebaceous adenomas (186.4 ± 25.0; p = 0.013).

Conclusions

Increased Nectin‐4 expression in a subset of cutaneous adnexal carcinomas, particularly sebaceous carcinomas, reveals that EV is a potential therapeutic option for these tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma, PapillaryAntibodies, MonoclonalNectinsNeoplasms, Adnexal and Skin AppendageSkin NeoplasmsHumansAdenomaCarcinoma, DuctalCarcinoma, Skin AppendageCarcinoma, Transitional CellSebaceous Gland NeoplasmsSweat Gland Neoplasms

Stichwörter der Autor:innen

Nectin‐4digital papillary adenocarcinomaenfortumab vedotinsebaceous carcinomasquamoid eccrine ductal carcinoma

Substanzen

Antibodies, Monoclonalenfortumab vedotinNectins

Autor:innen und Institutionen

  • Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Orbital Oncology & Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Woo Cheal Cho, Priyadharsini Nagarajan, Phyu P Aung, Mario L Marques-Piubelli, Doina Ivan, Carlos A Torres-Cabala, Omar Alhalabi, Victor G Prieto, Jonathan L Curry

Zitieren

APA

Cho, W. C., Saade, R., Nagarajan, P., Aung, P. P., Milton, D. R., Marques-Piubelli, M. L., Hudgens, C., Ledesma, D., Nelson, K., Ivan, D., Zhang, M., Torres-Cabala, C. A., Campbell, M., Alhalabi, O., Prieto, V. G., Wistuba, I. I., Esmaeli, B., & Curry, J. L. (2024). Nectin‐4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.14579

Vancouver

Cho WC, Saade R, Nagarajan P, Aung PP, Milton DR, Marques-Piubelli ML, et al. Nectin‐4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin. Journal of Cutaneous Pathology. 2024. doi:10.1111/cup.14579

BibTeX
@article{Cho2024,
  author = {Cho, Woo Cheal and Saade, Rayan and Nagarajan, Priyadharsini and Aung, Phyu P and Milton, Denái R and Marques-Piubelli, Mario L and Hudgens, Courtney and Ledesma, Debora and Nelson, Kelly and Ivan, Doina and Zhang, Miao and Torres-Cabala, Carlos A and Campbell, Matthew and Alhalabi, Omar and Prieto, Victor G and Wistuba, Ignacio I and Esmaeli, Bita and Curry, Jonathan L},
  title = {Nectin‐4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin},
  journal = {Journal of Cutaneous Pathology},
  year = {2024},
  doi = {10.1111/cup.14579}
}
Kostenlos starten →